KA/EN
Register
Medicines reference
Search
Search
Active substance

Arpraziquantel

Favourites

Pyrazinoisoquinoline anthelmintic. No registration in force in Georgia. Forms: tablet.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Arpraziquantel
Georgian name
არპრაზიკვანტელი (R-პრაზიკვანტელი)
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
0 of 5 forms
Products
Supramil
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration5

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Supramil, Tablet

milbemycin oxime 1.25 mg + R-praziquantel 6.25 mg, tablet for dogs up to 5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
6.8/10
Situational / acceptable
vetman assessment

Supramil

milbemycin oxime 1.25 mg + R-praziquantel 6.25 mg, tablet for dogs up to 5 kg
Assessed clinical scopeDog · Full labelled species-specific scope for susceptible intestinal cestodes and nematodes and prevention of Dirofilaria immitis infection, with combined use only when both active components are justified · By mouth
Care settingWeight-band tablet used after accurate weighing, parasite and heartworm-risk assessment, and review of the exact current package instruction
vetman score 6.8/10 Situational / acceptable
Evidence confidence: Low Georgia: Expired · № 002533 · Verified on 15 Oct 2026

A practical broad anthelmintic with direct exact-brand field data, but no Georgian registration is currently in force and its evidence and regulatory transparency remain materially thinner than for mature internationally assessed alternatives.

Regulatory and scientific credibility5.5/10

The Georgian register snapshot lists the exact authorisations only through 15-20 October 2026, with no renewal verified as of assessment. The forms appear in the current Russian national instruction but lack an EMA/FDA/VMD-style public assessment dossier and broad international regulatory history.

Clinical efficacy7.5/10

A manufacturer-linked 2019 controlled field report directly studied the exact species presentations and reported complete clearance across susceptible intestinal helminths; the established milbemycin-combination literature is supportive, but independent peer-reviewed exact-brand evidence is limited.

Safety and tolerability6.5/10

The established active ingredients have a generally predictable safety profile at labelled doses, but exact-brand safety evidence is mainly limited to small short-term groups. Microfilaraemic animals can react, MDR1-sensitive dogs require strict dosing, and renal, hepatic, age and weight restrictions apply.

Clinical practicality8.0/10

Small flavoured weight-band tablets and single-dose intestinal-worm treatment are practical; accurate weighing, administration with food and parasite-specific monthly prevention or repeat schedules remain necessary.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use the fixed combination only when its cestode and nematode or heartworm-prevention components are jointly justified; avoid unnecessary exposure to either active substance.
  • Before heartworm prevention in an endemic area, establish infection and microfilariae status. Do not interpret the small 2019 microfilaricidal study as support for adulticide treatment of established heartworm disease.
  • Use caution with other macrocyclic lactones or P-glycoprotein substrates/inhibitors; susceptible animals may have a narrower safety margin.
  • Control intermediate hosts for Dipylidium and follow local zoonosis procedures for Echinococcus; an anthelmintic dose alone does not prevent reinfection.
  • Weigh accurately and observe the exact minimum age and weight restrictions. In Collies, related breeds or suspected MDR1 deficiency, never exceed the current label dose; avoid use in marked renal or hepatic dysfunction unless the verified label permits it.
Assessment sources
  1. Rosselkhoznadzor 20242024
  2. Supramil clinical report 20192019
  3. Milbemax Thelazia RCT2012
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Milbemycin oxime1.25 mg Arpraziquantel6.25 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Astrafarm · Russia
Registration
Georgia Expired
Expired on 15 Oct 2026, not renewed yet
Veterinary (National Food Agency)
In the register: სუპრამილი® ტაბლეტები - 5კგ-მდე ლეკვებისა და ძაღლებისათვის
№ 002533
Verified on: 15 Oct 2026
 EU No
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Supramil, Tablet

milbemycin oxime 2 mg + R-praziquantel 2.5 mg, tablet for cats up to 2 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
6.8/10
Situational / acceptable
vetman assessment

Supramil

milbemycin oxime 2 mg + R-praziquantel 2.5 mg, tablet for cats up to 2 kg
Assessed clinical scopeCat · Full labelled species-specific scope for susceptible intestinal cestodes and nematodes and prevention of Dirofilaria immitis infection, with combined use only when both active components are justified · By mouth
Care settingWeight-band tablet used after accurate weighing, parasite and heartworm-risk assessment, and review of the exact current package instruction
vetman score 6.8/10 Situational / acceptable
Evidence confidence: Low Georgia: Expired · № 002534 · Verified on 15 Oct 2026

A practical broad anthelmintic with direct exact-brand field data, but no Georgian registration is currently in force and its evidence and regulatory transparency remain materially thinner than for mature internationally assessed alternatives.

Regulatory and scientific credibility5.5/10

The Georgian register snapshot lists the exact authorisations only through 15-20 October 2026, with no renewal verified as of assessment. The forms appear in the current Russian national instruction but lack an EMA/FDA/VMD-style public assessment dossier and broad international regulatory history.

Clinical efficacy7.5/10

A manufacturer-linked 2019 controlled field report directly studied the exact species presentations and reported complete clearance across susceptible intestinal helminths; the established milbemycin-combination literature is supportive, but independent peer-reviewed exact-brand evidence is limited.

Safety and tolerability6.5/10

The established active ingredients have a generally predictable safety profile at labelled doses, but exact-brand safety evidence is mainly limited to small short-term groups. Microfilaraemic animals can react, MDR1-sensitive dogs require strict dosing, and renal, hepatic, age and weight restrictions apply.

Clinical practicality8.0/10

Small flavoured weight-band tablets and single-dose intestinal-worm treatment are practical; accurate weighing, administration with food and parasite-specific monthly prevention or repeat schedules remain necessary.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use the fixed combination only when its cestode and nematode or heartworm-prevention components are jointly justified; avoid unnecessary exposure to either active substance.
  • Before heartworm prevention in an endemic area, establish infection and microfilariae status. Do not interpret the small 2019 microfilaricidal study as support for adulticide treatment of established heartworm disease.
  • Use caution with other macrocyclic lactones or P-glycoprotein substrates/inhibitors; susceptible animals may have a narrower safety margin.
  • Control intermediate hosts for Dipylidium and follow local zoonosis procedures for Echinococcus; an anthelmintic dose alone does not prevent reinfection.
  • Weigh accurately and use only the matching feline tablet. Observe the exact minimum age and weight restrictions, and avoid use in marked renal or hepatic dysfunction unless the verified label permits it.
Assessment sources
  1. Rosselkhoznadzor 20242024
  2. Supramil clinical report 20192019
  3. Milbemax Thelazia RCT2012
  4. Milbemax Toxocara cat study2007
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Milbemycin oxime2 mg Arpraziquantel2.5 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Astrafarm · Russia
Registration
Georgia Expired
Expired on 15 Oct 2026, not renewed yet
Veterinary (National Food Agency)
In the register: სუპრამილი® ტაბლეტები - 2კგ-მდე კატებისა და კნუტებისთვის
№ 002534
Verified on: 15 Oct 2026
 EU No
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Supramil, Tablet

milbemycin oxime 5 mg + R-praziquantel 25 mg, tablet for dogs up to 20 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
6.8/10
Situational / acceptable
vetman assessment

Supramil

milbemycin oxime 5 mg + R-praziquantel 25 mg, tablet for dogs up to 20 kg
Assessed clinical scopeDog · Full labelled species-specific scope for susceptible intestinal cestodes and nematodes and prevention of Dirofilaria immitis infection, with combined use only when both active components are justified · By mouth
Care settingWeight-band tablet used after accurate weighing, parasite and heartworm-risk assessment, and review of the exact current package instruction
vetman score 6.8/10 Situational / acceptable
Evidence confidence: Low Georgia: Expired · № 002532 · Verified on 15 Oct 2026

A practical broad anthelmintic with direct exact-brand field data, but no Georgian registration is currently in force and its evidence and regulatory transparency remain materially thinner than for mature internationally assessed alternatives.

Regulatory and scientific credibility5.5/10

The Georgian register snapshot lists the exact authorisations only through 15-20 October 2026, with no renewal verified as of assessment. The forms appear in the current Russian national instruction but lack an EMA/FDA/VMD-style public assessment dossier and broad international regulatory history.

Clinical efficacy7.5/10

A manufacturer-linked 2019 controlled field report directly studied the exact species presentations and reported complete clearance across susceptible intestinal helminths; the established milbemycin-combination literature is supportive, but independent peer-reviewed exact-brand evidence is limited.

Safety and tolerability6.5/10

The established active ingredients have a generally predictable safety profile at labelled doses, but exact-brand safety evidence is mainly limited to small short-term groups. Microfilaraemic animals can react, MDR1-sensitive dogs require strict dosing, and renal, hepatic, age and weight restrictions apply.

Clinical practicality8.0/10

Small flavoured weight-band tablets and single-dose intestinal-worm treatment are practical; accurate weighing, administration with food and parasite-specific monthly prevention or repeat schedules remain necessary.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use the fixed combination only when its cestode and nematode or heartworm-prevention components are jointly justified; avoid unnecessary exposure to either active substance.
  • Before heartworm prevention in an endemic area, establish infection and microfilariae status. Do not interpret the small 2019 microfilaricidal study as support for adulticide treatment of established heartworm disease.
  • Use caution with other macrocyclic lactones or P-glycoprotein substrates/inhibitors; susceptible animals may have a narrower safety margin.
  • Control intermediate hosts for Dipylidium and follow local zoonosis procedures for Echinococcus; an anthelmintic dose alone does not prevent reinfection.
  • Weigh accurately and observe the exact minimum age and weight restrictions. In Collies, related breeds or suspected MDR1 deficiency, never exceed the current label dose; avoid use in marked renal or hepatic dysfunction unless the verified label permits it.
Assessment sources
  1. Rosselkhoznadzor 20242024
  2. Supramil clinical report 20192019
  3. Milbemax Thelazia RCT2012
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Milbemycin oxime5 mg Arpraziquantel25 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Astrafarm · Russia
Registration
Georgia Expired
Expired on 15 Oct 2026, not renewed yet
Veterinary (National Food Agency)
In the register: სუპრამილი® ტაბლეტები“ 20კგ-მდე ლეკვებისა და ძაღლებისათვის
№ 002532
Verified on: 15 Oct 2026
 EU No
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Supramil, Tablet

milbemycin oxime 8 mg + R-praziquantel 10 mg, tablet for cats from 2 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
6.8/10
Situational / acceptable
vetman assessment

Supramil

milbemycin oxime 8 mg + R-praziquantel 10 mg, tablet for cats from 2 kg
Assessed clinical scopeCat · Full labelled species-specific scope for susceptible intestinal cestodes and nematodes and prevention of Dirofilaria immitis infection, with combined use only when both active components are justified · By mouth
Care settingWeight-band tablet used after accurate weighing, parasite and heartworm-risk assessment, and review of the exact current package instruction
vetman score 6.8/10 Situational / acceptable
Evidence confidence: Low Georgia: Expired · № 002536 · Verified on 15 Oct 2026

A practical broad anthelmintic with direct exact-brand field data, but no Georgian registration is currently in force and its evidence and regulatory transparency remain materially thinner than for mature internationally assessed alternatives.

Regulatory and scientific credibility5.5/10

The Georgian register snapshot lists the exact authorisations only through 15-20 October 2026, with no renewal verified as of assessment. The forms appear in the current Russian national instruction but lack an EMA/FDA/VMD-style public assessment dossier and broad international regulatory history.

Clinical efficacy7.5/10

A manufacturer-linked 2019 controlled field report directly studied the exact species presentations and reported complete clearance across susceptible intestinal helminths; the established milbemycin-combination literature is supportive, but independent peer-reviewed exact-brand evidence is limited.

Safety and tolerability6.5/10

The established active ingredients have a generally predictable safety profile at labelled doses, but exact-brand safety evidence is mainly limited to small short-term groups. Microfilaraemic animals can react, MDR1-sensitive dogs require strict dosing, and renal, hepatic, age and weight restrictions apply.

Clinical practicality8.0/10

Small flavoured weight-band tablets and single-dose intestinal-worm treatment are practical; accurate weighing, administration with food and parasite-specific monthly prevention or repeat schedules remain necessary.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use the fixed combination only when its cestode and nematode or heartworm-prevention components are jointly justified; avoid unnecessary exposure to either active substance.
  • Before heartworm prevention in an endemic area, establish infection and microfilariae status. Do not interpret the small 2019 microfilaricidal study as support for adulticide treatment of established heartworm disease.
  • Use caution with other macrocyclic lactones or P-glycoprotein substrates/inhibitors; susceptible animals may have a narrower safety margin.
  • Control intermediate hosts for Dipylidium and follow local zoonosis procedures for Echinococcus; an anthelmintic dose alone does not prevent reinfection.
  • Weigh accurately and use only the matching feline tablet. Observe the exact minimum age and weight restrictions, and avoid use in marked renal or hepatic dysfunction unless the verified label permits it.
Assessment sources
  1. Rosselkhoznadzor 20242024
  2. Supramil clinical report 20192019
  3. Milbemax Thelazia RCT2012
  4. Milbemax Toxocara cat study2007
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Milbemycin oxime8 mg Arpraziquantel10 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Astrafarm · Russia
Manufacturer (register)
Scientific Innovative Enterprise Astrafarm Ltd, Russia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 485, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Expired
Expired on 20 Oct 2026, not renewed yet
Veterinary (National Food Agency)
In the register: სუპრამილი® ტაბლეტები - 2კგ-დან კატებისთვის
№ 002536
Verified on: 15 Oct 2026
 EU No
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Supramil, Tablet

milbemycin oxime 12.5 mg + R-praziquantel 62.5 mg, tablet for dogs 20-50 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
6.1/10
Situational / acceptable
vetman assessment

Supramil

milbemycin oxime 12.5 mg + R-praziquantel 62.5 mg, tablet for dogs 20-50 kg
Assessed clinical scopeDog · Full labelled species-specific scope for susceptible intestinal cestodes and nematodes and prevention of Dirofilaria immitis infection, with combined use only when both active components are justified · By mouth
Care settingWeight-band tablet used after accurate weighing, parasite and heartworm-risk assessment, and review of the exact current package instruction
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Low Georgia: Expired · № 002535 · Verified on 15 Oct 2026

Direct but limited exact-form evidence prevents dismissal, yet both the expired Georgian certificate and the current-label mismatch materially weaken confidence; use only after confirming the current pack, dose table and legal status.

Regulatory and scientific credibility4.5/10

The Georgian register snapshot lists authorisation 002535 only through 19 October 2026, and no renewal has been verified as of assessment. The form was directly studied in 2019 but is absent from the current 2024 Russian national instruction, which now lists only four other presentations.

Clinical efficacy6.5/10

A manufacturer-linked 2019 controlled field report directly studied this strength and reported complete clearance in small groups, including microfilariae; however, it is not peer reviewed, sample sizes were small and the current national label no longer lists this presentation.

Safety and tolerability6.5/10

The established active ingredients have a generally predictable safety profile at labelled doses, but exact-brand safety evidence is mainly limited to small short-term groups. Microfilaraemic animals can react, MDR1-sensitive dogs require strict dosing, and renal, hepatic, age and weight restrictions apply.

Clinical practicality7.5/10

The large-dog tablet is convenient in principle, but the discrepancy between the registered presentation, the 2019 study and the current national instruction makes the current package dosing table essential before use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use the fixed combination only when its cestode and nematode or heartworm-prevention components are jointly justified; avoid unnecessary exposure to either active substance.
  • Before heartworm prevention in an endemic area, establish infection and microfilariae status. Do not interpret the small 2019 microfilaricidal study as support for adulticide treatment of established heartworm disease.
  • Use caution with other macrocyclic lactones or P-glycoprotein substrates/inhibitors; susceptible animals may have a narrower safety margin.
  • Control intermediate hosts for Dipylidium and follow local zoonosis procedures for Echinococcus; an anthelmintic dose alone does not prevent reinfection.
  • This 12.5/62.5 mg presentation has an expired Georgian certificate and appears in the 2019 exact-brand report, but not in the current 2024 Russian national instruction. Confirm the physical pack, current leaflet, dose table and legal authorisation before prescribing.
Assessment sources
  1. Rosselkhoznadzor 20242024
  2. Supramil clinical report 20192019
  3. Milbemax Thelazia RCT2012
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Milbemycin oxime12.5 mg Arpraziquantel62.5 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Astrafarm · Russia
Manufacturer (register)
Scientific Innovative Enterprise Astrafarm Ltd, Russia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 484, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Expired
Expired on 19 Oct 2026, not renewed yet
Veterinary (National Food Agency)
In the register: სუპრამილი® ტაბლეტები - 20კგ-დან 50კგ-მდე ძაღლებისთვის
№ 002535
Verified on: 15 Oct 2026
 EU No
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗